Archive · 27 Aug 2026
Aragen Life Sciences Files DRHP With SEBI for IPO
Aragen Life Sciences wants to sell shares to the public through an IPO.
It has filed a draft document with SEBI, India’s securities regulator.
The company helps pharmaceutical and biotechnology businesses discover, develop and manufacture medicines.
It works with both small-molecule drugs and biologic medicines.
Aragen said it served 591 customers around the world in fiscal 2026.
It also said 16 of the 20 largest pharmaceutical companies were among its customers.
Its revenue and profit increased during the year.
Several investment banks will help manage the proposed share sale.
Aragen Life Sciences has filed a Draft Red Herring Prospectus with SEBI for a proposed initial public offering.
The company provides contract research, development and manufacturing services for small molecules and biologics.
Aragen said it served 591 customers globally in fiscal 2026, including 16 of the top 20 Big Pharma companies.
Revenue from operations rose to Rs 2,178.39 crore and profit reached Rs 257.64 crore in FY26.
Axis Capital, Citigroup Global Markets India, Goldman Sachs (India) Securities and JM Financial are the issue’s lead managers.
- Who
- Aragen Life Sciences, a contract research, development and manufacturing company.
- What
- Filed a Draft Red Herring Prospectus with SEBI for a proposed IPO.
- When
- The filing date is not specified; the draft papers report fiscal 2026 figures.
- Where
- The company serves customers in the United States, Europe, Japan, India and other Asia-Pacific markets.
- Why
- To pursue a proposed public share offering; the articles do not state the specific use of IPO proceeds.
- Incorporation
- 2000
- FY26 revenue from operations
- Rs 2,178.39 crore
- FY26 profit for the year
- Rs 257.64 crore
- FY26 adjusted EBITDA
- Rs 593.77 crore
- FY26 adjusted profit
- Rs 283.99 crore
- Global customers in FY26
- 591
- Issue managers
- Axis Capital, Citigroup Global Markets India, Goldman Sachs (India) Securities and JM Financial